C. A. Aktipis, A. M. Boddy, R. A. Gatenby, J. S. Brown, and C. C. Maley, Life history trade-offs in cancer evolution, Nat. Rev. Cancer, vol.13, pp.883-892, 2013.

N. André, M. Carré, and E. Pasquier, Metronomics: towards personalized chemotherapy?, Nat. Rev. Clin. Oncol, vol.11, pp.413-431, 2014.

C. Becker, J. Hagmann, J. Müller, D. Koenig, O. Stegle et al., Spontaneous epigenetic variation in the arabidopsis thaliana methylome, Nature, vol.480, pp.245-249, 2011.

S. Benzekry, E. Pasquier, D. Barbolosi, B. Lacarelle, F. Barlési et al., Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine, Semin. Canc. Biol, vol.35, pp.53-61, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01195547

I. Bozic, B. Allen, and M. A. Nowak, Dynamics of targeted cancer therapy, Trends Mol. Med, vol.18, pp.311-316, 2012.

R. Brown, E. Curry, L. Magnani, C. S. Wilhelm-benartzi, and J. Borley, Poised epigenetic states and acquired drug resistance in cancer, Nat. Rev. Cancer, vol.14, p.747, 2014.

R. A. Burrell and C. Swanton, Tumour heterogeneity and the evolution of polyclonal drug resistance, Mol. Oncol, vol.8, pp.1095-1111, 2014.

B. A. Chabner and T. G. Roberts, Chemotherapy and the war on cancer, Nat. Rev. Cancer, vol.5, p.65, 2005.

N. Champagnat, R. Ferrière, and G. Ben-arous, The canonical equation of adaptive dynamics: a mathematical view, vol.2, pp.73-83, 2002.
URL : https://hal.archives-ouvertes.fr/inria-00164767

N. Champagnat, R. Ferrière, and S. Méléard, Unifying evolutionary dynamics: from individual stochastic processes to macroscopic models, Theor, Popul. Biol, vol.69, pp.297-321, 2006.

R. H. Chisholm, T. Lorenzi, and J. Clairambault, Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation, Biochim. Biophys. Acta, vol.1860, pp.2627-2645, 2016.

R. H. Chisholm, T. Lorenzi, L. Desvillettes, and B. D. Hughes, Evolutionary dynamics of phenotype-structured populations: from individual-level mechanisms to population-level consequences, Z. angew. Math. Phys, vol.67, pp.1-34, 2016.

R. H. Chisholm, T. Lorenzi, A. Lorz, A. K. Larsen, L. Almeida et al., Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, non-genetic instability and stress-induced adaptation, Cancer Res, vol.75, pp.930-939, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01111271

I. Dagogo-jack and A. T. Shaw, Tumour heterogeneity and resistance to cancer therapies, Nat. Rev. Clin. Oncol, vol.15, pp.81-94, 2018.

E. C. De-bruin, T. B. Taylor, and C. Swanton, Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications, Genome Med, vol.5, p.101, 2013.

R. D. Souza, P. Zahedi, R. M. Badame, C. Allen, and M. Piquette-miller, Chemotherapy dosing schedule influences drug resistance development in ovarian cancer, Mol. Canc. Therapeut, vol.10, pp.1289-1299, 2011.

M. Delitala and T. Lorenzi, A mathematical model for progression and heterogeneity in colorectal cancer dynamics, Theor, Popul. Biol, vol.79, pp.130-138, 2011.

, A mathematical model for the dynamics of cancer hepatocytes under therapeutic actions, J. Theor. Biol, vol.297, pp.88-102, 2012.

D. L. Dexter, H. M. Kowalski, B. A. Blazar, Z. Fligiel, R. Vogel et al., Heterogeneity of tumor cells from a single mouse mammary tumor, Cancer Res, vol.38, pp.3174-3181, 1978.

P. M. Enriquez-navas, Y. Kam, T. Das, S. Hassan, A. Silva et al., Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Sci. Transl. Med, vol.8, pp.327-351, 2016.

L. Euler, De integratione aequationum differentialium, Novi Commentarii Academiae Scientiarum Petropolitanae, vol.8, pp.3-33, 1763.

R. A. Gatenby, A change of strategy in the war on cancer, Nature, p.508, 2009.

R. A. Gatenby, A. S. Silva, R. J. Gillies, and B. R. Frieden, Adaptive therapy, vol.69, pp.4894-4903, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01887358

M. M. Gottesman, Mechanisms of cancer drug resistance, Annu. Rev. Med, vol.53, pp.615-627, 2002.

M. Greaves and C. C. Maley, Clonal evolution in cancer, Nature, pp.306-313, 2012.

D. Hanahan, G. Bergers, and E. Bergsland, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J. Clin. Investig, vol.105, pp.1045-1047, 2000.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

A. Hodgkinson, M. A. Chaplain, P. Domschke, and D. Trucu, Computational approaches and analysis for a spatio-structural-temporal invasive carcinoma model, Bull. Math. Biol, vol.80, pp.701-737, 2018.

C. Holohan, S. Van-schaeybroeck, D. B. Longley, and P. G. Johnston, Cancer drug resistance: an evolving paradigm, Nat. Rev. Cancer, vol.13, pp.714-726, 2013.

S. Huang, Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells, Cancer Metastasis Rev, vol.32, pp.423-448, 2013.

M. R. Junttila and F. J. De-sauvage, Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.501, pp.346-354, 2013.

G. Klement, S. Baruchel, J. Rak, S. Man, K. Clark et al., Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity, J. Clin. Investig, vol.105, pp.15-24, 2000.

K. S. Korolev, J. B. Xavier, and J. Gore, Turning ecology and evolution against cancer, Nat. Rev. Cancer, vol.14, pp.371-380, 2014.

O. Lavi, J. M. Greene, D. Levy, and M. M. Gottesman, The role of cell density and intratumoral heterogeneity in multidrug resistance, Cancer Res, vol.73, pp.7168-7175, 2013.

, Simplifying the complexity of resistance heterogeneity in metastasis, Trends Mol. Med, vol.20, pp.129-136, 2014.

R. J. Leveque, Finite difference methods for ordinary and partial differential equations: steady-state and time-dependent problems, Society for Industrial and Applied Mathematics (SIAM), 2007.

T. Lorenzi, R. H. Chisholm, and J. Clairambault, Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations, Biol. Direct, vol.11, pp.1-17, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01355314

T. Lorenzi, R. H. Chisholm, L. Desvillettes, and B. D. Hughes, Dissecting the dynamics of epigenetic changes in phenotype-structured populations exposed to fluctuating environments, J. Theor. Biol, vol.386, pp.166-176, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01237890

T. Lorenzi, C. Venkataraman, A. Lorz, and M. A. Chaplain, The role of spatial variations of abiotic factors in mediating intratumour phenotypic heterogeneity, J. Theor. Biol, vol.451, pp.101-110, 2018.

A. Lorz, T. Lorenzi, J. Clairambault, A. Escargueil, and B. Perthame, Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors, Bull. Math. Biol, vol.77, pp.1-22, 2015.
URL : https://hal.archives-ouvertes.fr/hal-00921266

A. Lorz, T. Lorenzi, M. E. Hochberg, J. Clairambault, and B. Perthame, Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies, ESAIM Math. Model. Numer. Anal, vol.47, pp.377-399, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00714274

J. P. Medema, Cancer stem cells: the challenges ahead, Nat. Cell Biol, vol.15, pp.338-344, 2013.

L. M. Merlo, J. W. Pepper, B. J. Reid, and C. C. Maley, Cancer as an evolutionary and ecological process, Nat. Rev. Cancer, issue.6, pp.924-935, 2006.

E. Moreno, Is cell competition relevant to cancer?, Nat. Rev. Cancer, vol.8, pp.141-147, 2008.

E. Munzone and M. Colleoni, Clinical overview of metronomic chemotherapy in breast cancer, Nat. Rev. Clin. Oncol, vol.12, pp.631-644, 2015.

N. E. Navin, Cancer genomics: one cell at a time, Genome Biol, vol.15, p.452, 2014.

J. Nocedal and S. Wright, Numerical optimization, 1999.

P. C. Nowell, The clonal evolution of tumor cell populations, Science, vol.194, pp.23-28, 1976.

H. Oey and E. Whitelaw, On the meaning of the word 'epimutation, Trends Genet, vol.30, pp.519-520, 2014.

A. Olivier and C. Pouchol, Combination of direct methods and homotopy in numerical optimal control: Application to the optimization of chemotherapy in cancer, J. Optim. Theor. Appl, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01568779

J. Otwinowski and J. B. Plotkin, Inferring fitness landscapes by regression produces biased estimates of epistasis, Proc. Natl. Acad. Sci. U.S.A, vol.111, pp.2301-2309, 2014.

B. Perthame, Transport equations in biology, 2006.

K. J. Pienta, N. Mcgregor, R. Axelrod, and D. E. Axelrod, Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments, Transl. Oncol, vol.1, pp.158-164, 2008.

A. Pisco and S. Huang, Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'what does not kill me strengthens me, Br. J. Cancer, vol.112, pp.1725-1732, 2015.

A. O. Pisco, A. Brock, J. Zhou, A. Moor, M. Mojtahedi et al., Nondarwinian dynamics in therapy-induced cancer drug resistance, Nat. Commun, vol.4, p.2467, 2013.

C. Pouchol, J. Clairambault, A. Lorz, and E. Trélat, Asymptotic analysis and optimal control of an integro-differential system modelling healthy and cancer cells exposed to chemotherapy, J. Math. Pures Appl, vol.116, pp.268-308, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01416594

R. Salgia and P. Kulkarni, The genetic/non-genetic duality of drug 'resistance'in cancer, Trends Cancer, vol.4, pp.110-118, 2018.

P. Savage, J. Stebbing, M. Bower, and T. Crook, Why does cytotoxic chemotherapy cure only some cancers?, Nat. Clin. Pract. Oncol, vol.6, pp.43-52, 2009.

O. G. Scharovsky, L. E. Mainetti, and V. R. Rozados, Metronomic chemotherapy: changing the paradigm that more is better, Curr. Oncol, vol.16, pp.7-15, 2009.

H. Schättler and U. Ledzewicz, Optimal control for mathematical models of cancer therapies, 2015.

S. V. Sharma, D. Y. Lee, B. Li, M. P. Quinlan, F. Takahashi et al., A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, pp.69-80, 2010.

R. T. Skeel and S. N. Khleif, Handbook of cancer chemotherapy, 2011.

R. E. Stace, T. Stiehl, M. A. Chaplain, A. Marciniak-czochra, and T. Lorenzi, A phenotype-structured individual-based model for the evolution of cancer cell populations under chemotherapy, 2019.

C. Sun, L. Wang, S. Huang, G. J. Heynen, A. Prahallad et al., Reversible and adaptive resistance to braf (v600e) inhibition in melanoma, Nature, vol.508, pp.118-122, 2014.

Y. Tamori and W. Deng, Cell competition and its implications for development and cancer, J. Genet. Genomics, vol.38, pp.483-495, 2011.

M. D. Thakur, F. Salangsang, A. S. Landman, W. R. Sellers, N. K. Pryer et al., Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance, Nature, pp.251-255, 2013.

N. C. Turner and J. S. Reis-filho, Genetic heterogeneity and cancer drug resistance, Lancet Oncol, vol.13, pp.178-185, 2012.

L. Wagstaff, G. Kolahgar, and E. Piddini, Competitive cell interactions in cancer: a cellular tug of war, Trends Cell Biol, vol.23, pp.160-167, 2013.

, We can obtain from equation (B.15) an explicit solution for µ i (t) when f i (0) < H i : µ i (t) = ? i + ? i (µ i